Jean-Pierre Garnier, the CEO at GlaxoSmithKline, is investing heavily on the R&D side of the business in a bid to gain the reputation as the Microsoft of the drug business. Garnier has already pushed research spending at the world's second-largest pharma company to 16 percent, or $4.4 billion, to develop new drugs. He plans to push that up to 20 to 25 percent. In an interview with the Independent, Garnier talks about GSK's brightest new blockbuster hopes and his firm belief that the company's pipeline will deliver a series of innovative new drugs that will vastly increase revenue.
- read the article on Garbier from the Independent